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The prevalence of hepatitis E virus (HEV) infec-
tions in Central Europe has been described only par-
tially and few studies report such data for this part of 
the European continent (Lapa et al., 2015). The knowl-
edge of this subject in Poland is limited to two reports 
discussing the seroprevalence of IgG antibodies in 
182 patients from Poznan center (anti-HEV-positivity in 
15.9% patients, EIA-gen HEV IgG kits; Adaltis, Milano, 
Italy) (Bura et al., 2015) and in 1016 hunters from all 
16 Polish provinces (anti-HEV detected in 20.3% par-
ticipants with ELISA recomWell HEV IgG kits; Micro-
gen, Neuried, Germany) (Sadkowska-Todys et al., 2015).
For another primary hepatotropic virus transmit-
ted by the fecal-oral route, that is, hepatitis A virus 
(HAV), in the 21st century, Poland has experienced 
a  shift toward very low endemicity (Magdzik and 
Czarkowski, 2004) and is currently one of the coun-
tries with the lowest hepatitis A incidence among the 
European Union member states (European Centre for 
Disease Prevention and Control, 2014).
A comparative study of HAV and HEV exposure 
markers (the presence of IgG antibodies against respec-
tive viruses) in 110 randomly selected healthy (HBV, 
HCV, HIV and syphilis-negative; no jaundice in the 
past) unpaid voluntary blood donors (BDs; 75 men 
and 35 women) living in Wielkopolska Region (Greater 
Poland; one of the largest regions in Poland, located in 
the west-central part of our country) was performed. 
The BDs were 19–58 years of age (38.4 ± 9.6; median 
age – 40 years).
Anti-HAV IgG (anti-HAV) seroprevalence was deter- 
 mined by a chemiluminescent microparticle immuno-
assay (CMIA; ARCHITECT HAV Ab-IgG kits; Abbott 
Laboratories, Wiesbaden, Germany) whereas for 
anti-HEV IgG (anti-HEV) WANTAI HEV-IgG ELISA 
kits (Wantai Biological Pharmacy Enterprise, Beijing, 
China) were used, both according to the manufac-
turers’ instructions. These tests are accepted diagnos-
tic tools for the assessment of exposure to HAV and 
HEV, respectively.
The serum samples were collected at the Regional 
Blood Center in Poznan, Poland, during the first 
6 months of 2015 and were stored at –20°C prior to 
testing.
All the BDs gave their written informed consent. 
The study was approved by the local Bioethics Com-
mittee (reference number: 263/15) and was funded 
by Poznan University of Medical Sciences (number of 
funds: 502-01-02205314-04519).
Numerical data were presented as mean and stand-
ard deviation. The comparison of age was performed 
by t-Student test. The assumption if data follow normal 
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The objective of the present study was to investigate the seroprevalence of HAV and HEV in Polish blood donors (BDs). One hundred and 
ten randomly selected healthy BDs, living in Wielkopolska Region were tested for anti-HAV IgG and anti-HEV IgG with commercial assays. 
The seroprevalence of anti-HAV was 11.8%; anti-HEV were detected in 60.9% of BDs (p < 0.0001). Consumption of risky food was more 
common in anti-HEV-positive BDs (59.1% vs. 33.3%; p = 0.01). Twelve out of 20 BDs (60%) with no history of travel abroad were exposed 
to HEV. Wielkopolska Region, Poland should be regarded as a new HEV infection-hyperendemic area in Europe.
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distribution was checked by Shapiro-Wilk’s test. The 
homogeneity of variances was checked by Levene’s test. 
Nominal data were compared by Chi-square test of inde-
pendence. For the factors that might influence the HEV 
seroprevalence odds ratios (OR) and 95% confidence 
intervals (CI) were calculated. Statistical analysis was 
performed with Statistica 12 (Statsoft, Inc.) software.
All tests were considered significant at p < 0.05.
The seroprevalence of anti-HAV was 11.8% (13/110), 
whereas anti-HEV were detected in 60.9% of BDs 
(67/110) (p < 0.0001); in 2 cases a borderline HEV anti-
bodies testing result was found and included as negative 
in further analysis.
The distribution of combined HAV and HEV IgG 
assessment results was as follows: double (anti-HAV/
anti-HEV) positive – 5 persons (4.5%), only anti-HAV-
positive – 8 BDs (7.3%), double negatives – 35 partici-
pants (31.8%) and only anti-HEV-positive – 62 persons 
(56.4%).
Anti-HAV-positive BDs were older (46.7 ± 6.8 years, 
range 38–58) than seronegatives (37.2 ± 9.4 years, range 
19–58) (p = 0.0006). 
For anti-HAV positive samples the mean ±SD rela-
tive light units (RLU) signal/cut off (s/co) ratio value was 
11.03 ± 3.16 (range 4.12–14.47; the positive result was 
defined as RLU s/co > 1.00) and for anti-HEV positive 
samples the mean optical density/cut off (OD/co) ratio 
value was 5.932 ± 3.454 (range 1.221–14.458; the positive 
result was defined as OD/co > 1.100; values between 0.9 
and 1.100 were considered borderline); it is worth to 
know that in only 9 HEV seropositive persons (13.4% 
out of all HEV-positive BDs) the OD/co ratio was lower 
than 2.000. The prevalence of some variables in relation 
to anti-HEV IgG status is shown in the Table I.
The main conclusion from the above analysis is that 
the culinary habits indicating the consumption of some 
risky food (raw / undercooked meat or seafood) were 
more common in the BDs exposed to HEV. This factor 
has been recognized as the source of infections with the 
zoonotic genotypes of the virus (Said et al., 2009; Man-
suy et al., 2011; Guillois et al., 2013; Meng, 2013). In 
addition, a trend toward a more frequent prevalence of 
anti-HAV in HEV-seronegative (vs HEV-seropositive) 
BDs in conjunction with a significantly less common 
presence of HAV exposure marker among the study 
participants suggest that the main modes of transmis-
sion for these viruses in our region are different.
Although there was no mean age difference between 
the study participants exposed to HEV and anti-HEV-
negatives (in our opinion, it was only because the group 
of BDs was small), the number of HEV-seropositive 
BDs aged > 30 tended to be higher than the prevalence 
of these antibodies in younger persons (see Table I). 
An evident relationship between the seroprevalence 
of HEV and age is reported in most available studies 
among BDs (Dreier and Juhl, 2014).
It should be stressed that in case of 20 persons 
with no history of travel abroad anti-HEV positivity 
was found in 60% of them (n = 12). It supports some 
previous suggestions (Bura et al., 2015) that autochtho-
nous (locally acquired) HEV infections do occur also 
in Poland.
Despite an obvious limitation of this study, that is, 
a small number of participants, its results are surpris-
ing because they indicate that Wielkopolska Region is 
a hyperendemic area for HEV infections. In Europe, 
similar seroprevalence of anti-HEV (52.5%) was found 
only in the Toulouse region, southwestern France 
(Mansuy et al., 2011). Such a high frequency of HEV-
seropositivity, significantly more important than found 
in previous surveys from our country in specific pop-
ulations (patients of Infectious Diseases Department 
Mean age ± SD [years] 39.5 ± 8.9 36.6 ± 10.3 NAb 0.1198Median age (IQRa) 41 (34 – 46) 37 (27 – 45)
BDs aged > 30 56 (83.6%) 29 (67.4%) 2.46 [0.99–6.09] 0.0523
Men 45 (67.2%) 30 (69.8%) 0.89 [0.39–2.02] 0.7749
Current place of residence – city 55 (82.1%) 35 (81.4%) 1.05 [0.35–3.29] 0.9233
Childhood place of residence – city  46 (69.7%) 29 (67.4%) 0.90 [0.37–2.25] 0.8038
Travel abroad during lifetime 55 (82.1%) 35 (81.4%) 1.05 [0.39–2.82] 0.9266
Contact with swine 12 (17.9%)  8 (19.1%) 0.93 [0.34–2.50] 0.8814
Anti-HAV positivity  5 (7.5%)  8 (18.6%) 2.83 [0.86–9.33] 0.0866
Consumption of raw / 39 (59.1%) 14 (33.3%) 2.89 [1.29–6.48] 0.0100undercooked meat or seafood
Table I
Status of anti-HEV and selected variables in 110 BDs from western Poland.
aIQR – interquartile range; bNA – not assessed.
Variable Anti-HEV+(n = 67)
Anti-HEV –
(n = 43) OR [95% CI] p
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and hunters) (Bura et al., 2015; Sadkowska-Todys et al., 
2015), can be explained by a very good sensitivity of the 
Wantai assay. Some seroprevalence assessments across 
Europe have shown that the use of these tests can result 
in several times higher ratios of anti-HEV in compari-
son to other manufacturers’ assays (Bendall et al., 2010; 
Mansuy et al., 2011; Wenzel et al., 2013).
Faced with such unexpected data, at least one ques-
tion of fundamental importance must be asked: what is 
the practical significance of such a common occurrence 
of HEV infections in Wielkopolska Region?
The answer is difficult because to the best of our 
knowledge none of the Polish hepatology centers has 
been performing tests for hepatitis E to date and there 
are no data on the prevalence of acute hepatitis of 
unknown etiology neither in our region nor Poland-
wide. Due to a very common subclinical exposure to 
HEV revealed by this study, a potential danger of HEV-
infected blood transfusions, particularly to immuno-
compromised recipients, should also be taken into 
account (Matsubayashi et al., 2004; Hewitt et al., 2014; 
Huzly et al., 2014). This issue should be rapidly clarified. 
In conclusion, the results of the current report sug-
gest that Wielkopolska Region, west-central Poland, 
should be regarded as a new HEV infection-hyperen-
demic area in Europe.
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